NASDAQ:MYGN Myriad Genetics Q3 2026 Earnings Date & Estimates $5.82 +0.06 (+1.04%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$5.86 +0.04 (+0.69%) As of 10/23/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Myriad Genetics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Myriad Genetics in Q3 2026Myriad Genetics is expected to post earnings of -$0.17 per share on revenue of $191.33 million. Myriad Genetics last reported on July 30, 2026, posting -$0.25 per share and missing the -$0.0579 consensus estimate. Myriad Genetics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.17Expected Revenue$191.33 millionRecent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.25 (Missed by -$0.1921)Last Quarter Revenue$190.70 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Myriad Genetics Q3 2026 Earnings FAQ When does Myriad Genetics report Q3 2026 earnings? Myriad Genetics (NASDAQ:MYGN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Myriad Genetics' Q3 2026 earnings call? Myriad Genetics' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Myriad Genetics? Analysts expect Myriad Genetics to post earnings of -$0.17 per share for Q3 2026. How much revenue is Myriad Genetics expected to report? The consensus revenue estimate for Myriad Genetics is $191.33 million for Q3 2026. Myriad Genetics Earnings HeadlinesMyriad Genetics consensus price target increased by 33.29% to $4.58October 23 at 11:32 PM | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Elevance Health (ELV) and Myriad Genetics (MYGN)October 23 at 8:28 AM | theglobeandmail.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 25 at 1:00 AM | Weiss Ratings (Ad)Myriad Genetics Reports New MRD Detection Data In Colorectal And Pancreatic CancersOctober 22 at 2:51 PM | rttnews.comMyriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst RevisionsOctober 22 at 2:51 PM | finance.yahoo.comMyriad Genetics: Prenatal Sale Provides A Lifeline In A Tough SpotOctober 22 at 9:11 AM | seekingalpha.comSee More Myriad Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Myriad Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Myriad Genetics and other key companies, straight to your email. Email Address About Myriad GeneticsMyriad Genetics (NASDAQ:MYGN) is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications. Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer. Myriad also offers GeneSight, a pharmacogenomic test intended to help inform medication selection for certain mental health conditions, as well as other diagnostic services designed to support personalized treatment and disease management. Founded in 1991, Myriad Genetics is headquartered in Salt Lake City, Utah. The company serves healthcare providers, patients, health systems, laboratories and pharmaceutical partners, primarily in the United States, with selected products and services available internationally. Nicole Lambert serves as the company’s president and chief executive officer.View Myriad Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-Off Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
